Pricing & Market Access Outlook 2015/2016 Edition

Click to view / download

Pricing and market access (P&MA) are key issues for the pharma industry as healthcare budgets continue to tighten and the value of innovative drugs, particularly in areas of high unmet need, becomes infinitely harder to assess.

Pharma and payers are pushing to find a balance between budget management and patient access. Pricing has consistently been a pressure point. This is even more extreme today with the shift to specialty products and treatment of rare diseases. As P&MA becomes central to commercialization, P&MA as a function is crucial to achieving leadership through this challenging environment. However, it is important that we not just identify trends – but as an industry we stay ahead of them and even influence their evolution. P&MA cannot be just a source of expertise within pharma – it needs to be a proactive leader of business results, shaping the future and engaging with stakeholders, and influencing decision-making.

The IMS Health P&MA Outlook report is an annual in-depth look at the major issues shaping the payer and reimbursement environment for global pharma products. The 2015/2016 edition contains 12 articles, selected and written by a team of in-house consultants, organized around four main themes.

Unlocking the globe

This section looks at the how the environment in the emerging market is changing for pharma, and how the healthcare systems are becoming more accessible and lucrative for those entering.